Sunday, July 30, 2006

MedImmune, Inc. - MedImmune Inc (MEDI) Starts Shipments of FluMist for 2006-07 Flu Season

MedImmune Inc (MEDI) Starts Shipments of FluMist for 2006-07 Flu Season

MedImmune, Inc. (Nasdaq: MEDI) announced that it is now shipping FluMist (Influenza Virus Vaccine Live, Intranasal) to customers for the 2006-2007 influenza season. FluMist is MedImmune's live, attenuated influenza vaccine (LAIV) approved for use in healthy individuals between 5 and 49 years of age.

Lentivector licensing agreement with Biogen Idec Inc

Lentivector licensing agreement with Biogen Idec Inc

Oxford BioMedica has entered into an agreement to license its LentiVector technology to Biogen Idec for use in research activities
Note: Readers of the Editor’s free email newsletter will have read this news when it was announced. Send us a blank email now to join the circulation. It’s free!
Oxford BioMedica will receive an upfront licence payment and an annual maintenance fee. Further financial details were not disclosed. LentiVector, a lentivirus-based system, is one of the most powerful technologies available for gene delivery to a wide range of cell and tissue types.

The technology has applications both in therapeutic products and drug discovery, as a tool for target validation and the creation of targeted disease models.

forest laboratories inc - Lexapro lawsuit filed against Forest Labs

Lexapro lawsuit filed against Forest Labs
AKRON, Ohio, July 26 (UPI) -- A lawsuit has been filed against U.S.-based Forest Laboratories involving the deaths of two men taking the drug company's antidepressant, Lexapro.

The lawsuit was filed by Mark and Lucy Bibbee, who claim Lexapro caused both their sons -- their only children -- to commit suicide 17 months apart, the Akron (Ohio) Beacon Journal reported.

Hospira, Inc. - Hospira Inc Hosts Conference Call for Second-Quarter 2006 Earnings

Hospira Hosts Conference Call for Second-Quarter 2006 Earnings
Thursday July 6, 11:00 am ET


Hospira, Inc. (NYSE: HSP - News), a leading global hospital products manufacturer, today announced that it will release its 2006 second-quarter results on Wednesday, Aug. 9, 2006, before the U.S. stock market opens.



A conference call for investors and media will be held at 9 a.m. Central Time, Wednesday, Aug. 9, 2006. A live webcast of the conference call will be available at www.hospirainvestor.com. Listeners should log on approximately 10 minutes in advance to ensure proper computer setup to receive the webcast. A replay will be available on the Hospira Web site for 30 days following the call.

About Hospira

Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM) by developing, manufacturing and marketing products that help improve the productivity, safety and efficacy of patient care. With 70 years of service to the hospital industry, Hospira's portfolio includes one of the industry's broadest lines of generic acute-care injectables, which help address the high cost of proprietary pharmaceuticals; integrated solutions for medication management and infusion therapy; and the leading U.S. injectable contract manufacturing business. Headquartered in Lake Forest, Ill., north of Chicago, Hospira has approximately 13,000 employees and 14 manufacturing facilities worldwide. Hospira's news releases and other information can be found at www.hospira.com.




--------------------------------------------------------------------------------
Source: Hospira, Inc

PowerShares Dynamic Biotech & Genome Portfolio

PowerShares Dynamic Biotech & Genome Portfolio (the Fund) is an index fund that seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Biotechnology & Genome Intellidex Index (the Biotechnology & Genome Intellidex). The Fund normally invests at least 80% of its total assets in common stocks of biotechnology companies and genome companies. The Fund normally invests at least 90% of its total assets in common stocks that comprise the Biotechnology & Genome Intellidex. The Biotechnology & Genome Intellidex consists of stocks of 30 United States biotechnology and genome companies.

Financials Quarterly (Apr '06) Annual (2006)
Income Statement
(in millions of USD) Total Revenue 0.09 0.12
Operating Income -0.56 -0.73
Net Income 0.27 -0.22

Balance Sheet
(in millions of USD) Total Assets 250.24 250.24
Total Liabilities 0.22 0.22
Total Equity 250.02 250.02

Cash Flow
(in millions of USD) Net Income/Starting Line 0.27 -0.22
Cash from Operating 0.27 -0.22
Cash from Financing 127.65 250.24
Net Change in Cash 127.92 250.02

Lentigen Corporation And The University Of Pennsylvania Announce Collaborative Research Agreement

Lentigen Corporation And The University Of Pennsylvania Announce Collaborative Research Agreement

Lentigen Corporation announced today the signing of a collaborative research agreement (CRA) with the University of Pennsylvania. Under the terms of this agreement, Lentigen will be working with James Riley, Ph.D., of the University of Pennsylvania School of Medicine on the development of novel cancer therapies.

Research in Dr. Riley's laboratory, which is located within the Department of Pathology and Lab Medicine, focuses on costimulatory pathways that control human T cell activation and differentiation. One major project focuses on signal transduction pathways initiated by members of the CD28 family (CD28, ICOS, CTLA-4, PD-1 and BTLA). These receptors, despite their structural similarity, play distinct roles in modulating the immune system.

Initial indications of this CRA will focus on how to use the knowledge of T cell signaling pathways to design novel cancer therapeutics and broaden to other indications over time. The collaboration will utilize Dr. Riley's scientific expertise and Lentigen's scientific and marketing expertise. Lentigen will be granted exclusive rights to commercialize resulting products. No financial terms of the agreement were disclosed.

Dr. Boro Dropulic, Founder and CEO of Lentigen, commented, "This collaborative research agreement with the University of Pennsylvania and Dr. Riley's laboratory will allow for potential commercialization of products developed by U Penn's School of Medicine. We are fortunate to have such a strong relationship with Dr. Riley and the research being done at the University of Pennsylvania in the area of gene therapy."

"This collaboration will permit the large-scale experiments that are required to move an idea from the bench to the bedside," said Dr. Riley, an Associate Professor of Pathology and Laboratory Medicine at Penn. "We are excited to work with Dr. Dropulic and his lentiviral technology."

About Lentiviral Vectors

Lentiviral vectors (LV) are vehicles that can deliver genes or RNAi into cells with up to 100% efficiency and stability. By comparison, other viral vector systems such as non-viral, adenoviral and adeno-associated viral vectors have not been shown to achieve both high and stable gene delivery in dividing cells.

Gene delivery is accomplished by the binding and fusing of the LV pseudotyped envelope protein to the target cell membrane. The LV RNA containing the gene or gene silencing sequence is then incorporated into the cell via reverse transcription creating a DNA complex. This complex enters the nucleus incorporating into the chromosomal DNA creating a stable molecule. The gene sequence is integrated in the chromosome and is copied along with the DNA during ongoing cell division.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology for a wide range of applications in biotechnology and medicine. Lentiviral vectors are highly adapted delivery vehicles that can transport genes or gene silencing sequences into cells with high efficiency and stability. Lentigen is positioning itself to become the leading provider of Lentiviral vector products and services for academic, government, biotechnology and pharmaceutical researchers. For further information, visit http://www.Lentigen.com.

Friday, July 28, 2006

Telik Inc Announces Initiation of New TELCYTA Phase 3 Clinical Trial and Updates Status of Ongoing Phase 3 Ovarian Cancer Clinical Trials - Telik, Inc

Telik Inc. Announces Initiation of New TELCYTA Phase 3 Clinical Trial and Updates Status of Ongoing Phase 3 Ovarian Cancer Clinical Trials
Tuesday May 2, 7:30 am ET


PALO ALTO, Calif., May 2 -- Telik, Inc. (Nasdaq: TELK - News) announced the initiation of ASSIST-5, an international Phase 3 clinical trial that will compare treatment with the combination of TELCYTA® and Doxil® to treatment with Doxil alone in women with platinum refractory or resistant ovarian cancer. Telik plans to enroll approximately 244 women with 122 randomized to each treatment arm. Trial endpoints include objective response rate, progression-free survival and overall survival. ASSIST-5 is based on the positive results previously reported from a multicenter Phase 2 study of the combination of TELCYTA plus Doxil in platinum refractory or resistant ovarian cancer.



"ASSIST-5 is an important step in the development program for TELCYTA since Doxil is a frequently prescribed second-line drug for ovarian cancer." said Michael Inouye, Senior Vice President, Commercial Operations. "If the trial is successful, it may offer additional treatment strategies for many patients initially treated with platinum-containing regimens."

Telik has two additional Phase 3 trials ongoing in platinum refractory or resistant ovarian cancer, ASSIST-1 and ASSIST-3. The ASSIST-1 trial is evaluating TELCYTA in third line platinum refractory or resistant ovarian cancer. Enrollment in this trial was completed in December 2004 and the pre- specified number of events has not occurred. Enrollment has recently been completed on the ASSIST-3 trial which is evaluating the combination of TELCYTA plus carboplatin versus Doxil in platinum refractory or resistant ovarian cancer.

About Telik

Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced drug development candidate is TELCYTA, a tumor-activated small molecule product candidate. TELCYTA is in four Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(TM), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.

This press release contains "forward-looking" statements, including statements regarding the potential for TELCYTA or TELINTRA to treat one or more types of cancer. There are important factors that could cause Telik's results to differ materially from those indicated by these forward-looking statements, including, among others, that none of Telik's product candidates have been determined to be safe or effective in humans or been approved for marketing, clinical trials of Telik's product candidates may take several years to complete and may not be successful, success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful and interim results of clinical trials do not necessarily predict final results. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2005. Telik does not undertake any obligation to update forward-looking statements contained in this press release.




--------------------------------------------------------------------------------
Source: Telik, Inc.

Biotech News

Thursday, July 27, 2006

Health Leaders Urge Improved Quality of Care for Black Patients with Heart Failure; New Initiative Monitors Compliance

Health Leaders Urge Improved Quality of Care for Black Patients with Heart Failure; New Initiative Monitors Compliance

Key medical, research and civil rights groups called a press conference today to endorse action in resolving the disparities faced by Black patients with chronic heart failure, and the necessity to provide the best modern therapy to this population. The leaders participating in the press conference represent the National Minority Health Month Foundation (NMHMF), the National Medical Association (NMA), the Association of Black Cardiologists (ABC), the Congressional Black Caucus Health BrainTrust, the Alliance of Minority Medical Associations (AMMA), the Institute for the Advancement of Multicultural and Minority Medicine (IAMMM), and the federal Centers for Medicare and Medicaid Services (CMS).

During the press conference, Mark B. McClellan, MD, PhD, CMS administrator, called in to voice his commitment to helping Black Medicare beneficiaries with heart failure receive best modern therapy as defined by clinical guidelines. In addition, NMHMF, the ABC, NMA, AMMA and the IAMMM announced the launch of a proactive national quality monitoring initiative, COMMUNITY HEARTBEAT! This resource will monitor and report on the quality of care for Black patients with heart failure, using BiDil(r) as a proxy for measuring quality care consistent with recommended clinical guidelines.

BiDil, a patented fixed-dose combination of isosorbide dinitrate and hydralazine, was approved by the U.S. Food and Drug Administration (FDA) as the first-ever treatment indicated for self-identified Black patients with heart failure. "In Washington, D.C. alone, we determined that approximately 2,000 diagnosed Black patients with heart failure were hospitalized in the past year," said Gary A. Puckrein, Ph.D., executive director, NMHMF. "However, the percentage of Black patients who are getting the drug treatment recommended by the American Heart Association/American College of Cardiologists Heart Failure Guidelines and the Heart Failure Society of America Treatment Guidelines, is only in the single digits. This is a treatment inadequacy that must be remedied."

Black Americans between the ages of 45 and 64 are more than twice as likely to die from heart failure than Caucasians and are affected by the disease at a much younger age. Alarmingly, Black patients with heart failure are not receiving standard treatments "All individuals should receive optimal health care to enable patients to live longer and better quality lives," said Sandra Gadson, M.D., president, National Medical Association. "We are here today to focus on eliminating disparities in access to at least the minimum standard of care for the more than 750,000 African American heart failure patients who suffer from this disease."

In a message from the CBC, Congresswoman Donna M. Christensen said that despite the documented benefits of BiDil, "many African Americans face barriers to access to BiDil. Some of these barriers are a funciton of misunderstanding abouth this drug treatment, which is why today's event is so critically important to raise awareness about recommended tratment for chronic heart failure among African Americans."

"The Association of Black Cardiologists endorses the AHA/ACC Guidelines, which document differential effectiveness of some treatments for specific patient populations," said Gerald DeVaughn, MD, ABC president. "Adherence to evidence-based treatment and practice guidelines will not only change how a Black patient with heart failure lives with the disease, but can also help reduce costs associated with avoided or delayed hospitalizations, time associated with office-based care and expenses for employers paying both short- and long-term disability benefits."

The effectiveness of the patented fixed dose combination of isosorbide dinitrate and hydralazine was studied in the African American Heart Failure Trial (A-HeFT). A-HeFT, the first study conducted in an all self-identified Black population demonstrated a significant survival benefit in patients taking the drug. FDA's approval of the drug last year triggered an unprecedented national debate about race, genomics, and the role of personalized medicine.

According to Randall W. Maxey, MD, PhD, president of the Alliance of Minority Medical Associations, "Genetic research in the past few decades has uncovered significant differences among racial and ethnic groups in the metabolism, clinical effectiveness, and side effect profiles of therapeutically important drugs. Clinicians and policy makers involved in research, clinical practice, and the development of prescription drug coverage and payment formularies must establish constructive partnerships to assure that all populations have access to the most effective treatments."

---

About the National Minority Health Month Foundation

Founded as a nonprofit organization in 1998, the National Minority Health Month Foundation was established to strengthen national and local efforts to eliminate the disproportionate burden of premature death and preventable illness in racial and ethnic minorities and other special populations through the use of evidence-based, data-driven initiatives.

Biotech News

IntraLase Names New Board Member; Michael Ball, President of Allergan, Inc., Joins IntraLase Board

IntraLase Names New Board Member; Michael Ball, President of Allergan, Inc., Joins IntraLase Board
IRVINE, Calif.--(BUSINESS WIRE)--July 25, 2006--IntraLase (NASDAQ:ILSE), manufacturer of the ultra-fast laser that is revolutionizing refractive and corneal surgery, today announced the appointment of Michael Ball to its board of directors.


"Mike is a great addition to an already outstanding board of directors," said Robert J. Palmisano, President and CEO of IntraLase. "His extensive experience in the global eye care industry will provide an excellent asset as we continue to implement our strategies for growth."

Mr. Ball, who has over 25 years of experience in the healthcare industry, is the President of Allergan, Inc., a global company that develops and commercializes products in the ophthalmology, neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty markets. Mr. Ball joined Allergan in April 1995 as Senior Vice President, U.S. Eye Care and was promoted to Corporate Vice President and President, North America Region in April 1996. In October 2003, Mr. Ball was promoted to Executive Vice President and President, Pharmaceuticals. In February 2006, Mr. Ball was promoted to President, Allergan. Prior to joining Allergan, Mr. Ball was Senior Vice President at Syntex Labs in Palo Alto, California, responsible for marketing, sales and managed care activities in the United States. Prior to that, Mr. Ball was President of Syntex Canada, a fully integrated division of Syntex Corporation. Mr. Ball started his career in the healthcare industry with Eli Lilly and Company.

Mr. Ball is also currently a board member of Simpletech, Inc. of Santa Ana, California.

IntraLase's board of directors also includes Chairman of the Board William J. Link, Ph.D., a Managing Director of Versant Ventures, a medical and healthcare venture capital firm, and a board member of Advanced Medical Optics, Inc.; Gilbert H. Kliman, M.D., a Managing Director of InterWest Partners, a venture capital firm, and a board-certified ophthalmologist; Thomas S. Porter, a General Partner of Trillium Ventures, a venture capital firm, Executive in Residence at the Ross School of Business at the University of Michigan, and a member of the University of Michigan's Corporate Advisory Board; Jay T. Holmes, an attorney and business consultant, former executive at Bausch and Lomb Incorporated, and a former board member of VISX, Incorporated; Frank M. Fischer, President and CEO of NeuroPace, Inc., and former President and CEO of Heartport, Inc.; and Robert J. Palmisano, President and CEO of IntraLase Corp.

Mr. Ball replaces Mr. Mark Lortz, who had served on IntraLase's board of directors for almost four years. In May 2006, Mr. Lortz announced his intention to resign from the Board and said he would not step down until a successor was available to fill the position. "We thank Mark Lortz for his many contributions in helping guide the Company through important transitions over the years, including our initial public offering in October 2004," stated Mr. Palmisano. "We wish Mark all the best in the future."

About IntraLase Corp.

IntraLase designs, develops, and manufactures an ultra-fast laser that is revolutionizing refractive and corneal surgery by creating safe and more precise corneal incisions. Delivering on the promise of ophthalmic laser technology, the IntraLase FS laser, related software, and disposable devices replace the hand-held microkeratome blade used during LASIK surgery. The unsurpassed accuracy of IntraLase's computer-controlled femtosecond laser has been shown to improve safety profiles and visual outcomes when used during LASIK. Additionally, the IntraLase FS laser creates precision-designed intracorneal incisions that when combined can be used during lamellar and penetrating keratoplasties, and intrastromal ring implantation. IntraLase is presently in the process of commercializing applications of its technology in the treatment of corneal diseases that require corneal transplant surgery. The company's proprietary laser and disposable patient interfaces are presently marketed throughout the United States and 30 other countries. IntraLase is headquartered and manufactures its products in Irvine, California. For additional information, visit the company's web site: www.intralase.com.

Forward-Looking Statements

Statements contained in this press release that are not historical information are forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "project," or words of similar meaning, or future or conditional verbs such as "will," "would," "should," "could," or "may." Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Those risks and uncertainties include, but are not limited to: the degree of continued acceptance of LASIK surgery; potential complications revealed by long-term follow up; the extent of adoption of our product offering by LASIK surgeons; general economic conditions; changes in federal tax laws governing the ability of potential LASIK patients to use pre-tax dollars to pay for LASIK surgery; the scope of government regulation applicable to our products; patients' willingness to pay for LASIK surgery; our ability to compete against our competitors; the effectiveness of our measures to ensure full payment of procedure fees; the occurrence and outcome of product liability suits against us; our ability to adequately protect our intellectual property; whether we become subject to claims of infringement or misappropriation of the intellectual property rights of others; the continued availability of supplies from single-source suppliers and manufacturers of our key laser components; the ability of our managers, operations, and facilities to manage our growth; the success of our expansion into markets outside the United States; whether we lose any of our key executives or fail to attract qualified personnel; or if our new products or applications fail to become commercially viable.

Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's quarterly report on Form 10-Q for the period ending March 31, 2006, as filed with the Securities and Exchange Commission on May 9, 2006.

These forward-looking statements are made only as of the date of this press release, and the company assumes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.



Biotech News

Celgene Gets Approvable Letter for sNDA for Thalomid®

Celgene Gets Approvable Letter for sNDA for Thalomid®

A supplemental new drug application (sNDA) has been deemed “approvable” by the Food and Drug Administration for Celgene’s Thalomid (thalidomide). The sNDA includes Thalomid for the initial treatment of multiple myeloma.

The sNDA approvable letter was based on results from a large phase III study that directly compared Thalomid plus dexamethasone to dexamethasone alone as initial therapy for multiple myeloma.

Thalomid is known to have anti-angiogenic properties as well as immune modulatory effects.

Zacks.com Announces That Jim Collins Highlights the Following Stocks: Intevac, Illumina, Hansen Natural Corporation and Celgene Corporation

Biotech News

Zacks.com Announces That Jim Collins Highlights the Following Stocks: Intevac, Illumina, Hansen Natural Corporation and Celgene Corporation

July 20, 2006--Jim Collins, editor of the OTC Insight newsletter, believes that fundamentals suggest stocks will eventually come back strong. Read about Intevac (Nasdaq:IVAC), Illumina (Nasdaq:ILMN), Hansen Natural Corporation (Nasdaq:HANS) and Celgene Corporation (Nasdaq:CELG). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84.


Highlights from the July 17 Featured Expert column by Jim Collins include:

A Sampling of Company News...

Intevac (Nasdaq:IVAC) shares are higher after the company said last Tuesday full-year sales would top previous projections. Earlier, the company announced it received orders from multiple customers for a total of eleven 200 Lean magnetic disk sputtering systems. Intevac said that with these orders they have booked enough systems to not only exceed the high end of their previous revenue guidance for 2006, but also provide an excellent start for 2007.

Illumina (Nasdaq:ILMN) has signed a genotyping services agreement with Johnson & Johnson Pharmaceutical Research & Development. Under the terms of the agreement, Illumina will develop custom SNP (single nucleotide polymorphism) content for a multi-sample Sentrix BeadChip. The BeadChip platform enables analysis of 12 samples and up to 60,000 SNPs per sample on a single BeadChip.

Stock Picks include...

Hansen Natural Corporation (Nasdaq:HANS) is a holding company and carries on no operating business except through its direct wholly-owned subsidiaries, Hansen Beverage Company and Hard e Beverage Company. Hansen is engaged in the business of marketing, selling and distributing so-called alternative beverage category, such as natural sodas, fruit juices, juice cocktails.

Celgene Corporation (Nasdaq:CELG) is an independent biopharmaceutical company engaged primarily in the discovery, development and commercialization of orally administered, small molecule drugs for the treatment of cancer and immunological diseases.

Read Jim Collins' outlook regarding the stock market's come back and receive more company news as well as stock picks by clicking: http://at.zacks.com/?id=85.

About Zacks Featured Experts

Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=87.

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Adams Respiratory Therapeutics Announces Plan to Repurchase Manufacturing Assets and Operations in Fort Worth, Texas, From Cardinal Health

Adams Respiratory Therapeutics Announces Plan to Repurchase Manufacturing Assets and Operations in Fort Worth, Texas, From Cardinal Health

Adams seeks to develop a world class manufacturing operation that consistently meets customer demand for its leading respiratory medicines


Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT - News) today announced that it has entered into a definitive agreement with Cardinal Health to repurchase the manufacturing assets and operations in Fort Worth, Texas, for approximately $28 million. Cardinal Health, Inc. (NYSE: CAH - News), a leading provider of products and services supporting the healthcare industry, originally purchased the manufacturing operations from Adams in 2004. Adams expects to take ownership of the facility from Cardinal Health on or about July 31, 2006.
ADVERTISEMENT


The Company expects to take a one-time pre-tax charge of between $8 and $10 million in the fiscal 2007 first quarter ending Sept. 30, 2006, depending on the final value of the assets and obligations of the transaction at closing. Adams plans to finance the plant buyback using a combination of cash on hand as well as debt financing. Upon closing of the transaction, Adams' management will conduct an investor conference call to provide further financial and other information regarding the plant buyback.

Commenting on the announcement, Michael J. Valentino, president and CEO said, "Looking back, the original decision to sell the Fort Worth facility to Cardinal Health in April 2004, was absolutely the right decision for our company at the time. With $14 million in annual net sales, we needed to focus our efforts on maximizing the commercial potential of our then newly approved product, Mucinex®. As a result of this sharp focus, we now consider sales, marketing and advertising core competencies of Adams and the Mucinex® brand has become a category leader. Two years later, with several products on the market and trailing-twelve-month net sales of more than $225 million as of Mar. 31, 2006, our business priorities have evolved. Now it is imperative that we make appropriate investments in people, processes and equipment, so that manufacturing becomes another core competency of Adams."

Valentino added, "We look forward to welcoming about 270 new Texas-based employees to Adams and we're delighted to welcome back those employees who have continued to work in the plant since the original sale in 2004. In addition, we would like to thank our strategic partner, Cardinal Health, for their expertise in pharmaceutical manufacturing and packaging, and their ability to quickly respond to rapidly increasing demand as a result of the nearly 15-fold growth in our sales over the past couple of years. We greatly appreciate their efforts and hope to further strengthen our relationship by leveraging their high-quality manufacturing, supply and packaging capabilities within their company."

Financial Terms of the Plant Buyback

The financial terms of the agreement consist of cash payments of approximately $28 million, of which about $24 million will be paid upon the anticipated closing on or about July 31, and the remainder to be paid quarterly during fiscal year 2007. The re-acquisition payments will include purchases of manufacturing assets, raw material, work-in-process inventory and non-recurring expenses. The Company expects to take a one-time pre-tax charge of between $8 and $10 million during the 2007 fiscal first quarter ending Sept. 30, 2006, depending on the final value of the assets and obligations of the transaction at closing. Adams plans to finance the plant buyback using a combination of cash on hand as well as debt financing.

In addition, Adams and Cardinal Health have entered into separate manufacturing supply agreements for granulation capacity at Cardinal Health's Winchester, Kentucky, facility and packaging capacity at two other Cardinal Health facilities. These facilities have previously been validated and are operational with respect to the Company's Mucinex® and Humibid® guaifenesin-based extended-release bi-layer tablet products.

Commenting on the financial benefits of the plant buyback, David P. Becker, executive vice president, CFO and treasurer said, "We are excited about this transaction and the opportunity to make critical investments in the future growth of our business. We will be focused on investing in our people, processes and equipment to expand production capacity and extract efficiencies that may lead to future reductions in production costs." Becker added, "As a result of this transaction, our gross margin is expected to increase by about 2 percentage points for those products produced in Fort Worth, beginning in fiscal 2007."

Manufacturing Operation in Forth Worth, Texas

The 130,000 square foot facility in Fort Worth, Texas, is the primary manufacturing and product packaging facility for the Company's Mucinex® and Humibid® franchise of guaifenesin-based extended-release bi-layer tablet products. There are currently approximately 270 employees based at the Fort Worth facility.

Adams seeks to develop a world class manufacturing operation in Forth Worth, Texas that consistently meets customer demand for its leading respiratory medicines.

About Adams Respiratory Therapeutics, Inc.

Adams is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

Forward-Looking Statements

This press release contains certain "forward-looking" statements, including the Company's ability to make manufacturing a core competency, expand manufacturing capacity, realize manufacturing efficiencies, reduce product costs, increase gross margin for products manufactured at the Fort Worth facility and consistently meet customer demand for its products. Such forward-looking statements can be identified by the words "expect," "plan," "seeks," "believe," "intend," and similar expressions and are subject to risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially include, among others, the Company's ability to: operate efficiently the Fort Worth manufacturing facility and develop manufacturing as a core competency, make appropriate investments in manufacturing people, processes and equipment, realize manufacturing efficiencies, reduce production costs, increase the gross margin for products manufactured in Fort Worth, and consistently meet customer demand for its products; and other risk factors set forth under the headings "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Adams' Rule 424(b)(4) Prospectus filed with the SEC on December 9, 2005 and under Item 1A. Risk Factors in Adams' Quarterly Report on Form 10-Q for the period ended March 31, 2006. Except to the extent required by applicable securities laws, Adams is not under any obligation to (and expressly disclaims any such obligation to) update its forward-looking statements, whether as a result of new information, future events, or otherwise. All statements contained in this press release are made only as of the date of this presentation.




--------------------------------------------------------------------------------
Source: Adams Respiratory Therapeutics, Inc.

MedivoxRx Technologies Brings Rex-The Talking Prescription Bottle to Las Vegas for Cardinal Health - Retail Business Conference

MedivoxRx Technologies Brings Rex-The Talking Prescription Bottle to Las Vegas for Cardinal Health - Retail Business Conference


Jul 27, 2006 - MedivoxRx Technologies Inc., a division of Wizzard Software Corp. (OTCBB:WIZD), has announced they are currently presenting Rex-The Talking Prescription Bottle at the 16th Annual Cardinal Health Retail Business Conference (RBC) 2006 at the MGM Grand in Las Vegas. Located at booth 304, MedivoxRx Technologies is one of the more than 275 suppliers featured during the trade show. At last year's conference, Cardinal hosted more than 1,400 independent and community pharmacies, with 4,000 pharmacists, pharmacy technicians and other pharmacy industry professionals in attendance.

Throughout the week, MedivoxRx is showcasing the Rex Pharmacy System. Using the microphone recording units, prescription label information is recorded to the Rex bottle through microelectronic technology embedded in the base of each bottle. In addition to label information, other important or helpful information may be recorded into the bottle. To playback the recorded information, users simply press a button on the side of the bottle and listen to the message.



Cardinal Health customers can order Rex Bottles (Case of 24 Talking Bottles - CHI # 3675204) and Recorders (Recorder with Microphone - CHI # 3675246) during the show at the MedivoxRx booth.

Also available from MedivoxRx is the Rex Pharmacy Software. Full automation through text-to-speech technology allows pharmacists to automatically record the medication information to the Rex bottle in a natural-sounding computer generated voice using the pharmacy's current software and data. When the pharmacist releases the medication instructions to the standard label printer, the MedivoxRx software captures that text, converts it to speech and records it into the bottle.

"We are very excited to be exhibiting at Cardinal Health RBC," said Gene Franz, General Manager of Solutions and Channels for MedivoxRx. "It's a fantastic opportunity to put Rex in front of so many Cardinal Health (NYSE:CAH) customers and inform them on the benefits of providing their patients with an easy-to-use, cost-effective device that can help manage prescriptions, safeguard health and save lives."

Rex-The Talking Prescription Bottle contributes a solution to the growing medication error problem in the United States. The Journal of the American Medical Association reports medication errors and/or adverse drug events kill an estimated 100,000 persons annually and represent the fourth leading cause of death in the U.S. The first three are heart disease, cancer, and stroke.

Further, Rex is a useful tool for the numerous individuals who take multiple medications. According to an AARP survey, people ages 45 and over take 4 prescription medications per day. Also, a report issued by the National Center for Health Statistics released in 2004 estimates more than 20 percent of all patients age 75 and older were taking five or more prescription drugs. While the average number of prescription drugs a 75 year old takes each day is 5, in many instances older people are using 12 or more prescriptions.

About Wizzard Software:

Founded in 1996, Wizzard Software has become a leader in the speech technology application development market. Wizzard architects solutions to business problems using its expertise in consulting, speech development tools and building speech based applications for the Desktop and Internet. Wizzard has achieved global recognition because of its expertise with voice communication whether it is via PC or telephone. Wizzard's successes have lead to expanding opportunities in both the government and commercial sectors. In April of 2004, Wizzard acquired MedivoxRx Technologies. Established in 2000, MedivoxRx is the originator of "Rex", the talking prescription pill bottle, which "talks" to the patient allowing them to distinguish what type of medication is in the bottle and hear critical information on dosage amounts and refill parameters. Additional information on MedivoxRx can be found at www.rxtalks.com. More information on Wizzard Software can be found on the Investor's Page at www.wizzardsoftware.com.

Legal Notice

Legal Notice Regarding Forward-Looking Statements: "Forward-looking Statements" as defined in the Private Securities litigation Reform Act of 1995 may be included in this news release. These statements relate to future events or our future financial performance. These statements are only predictions and may differ materially from actual future results or events. We disclaim any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise. There are important risk factors that could cause actual results to differ from those contained in forward-looking statements, including, but not limited to risks associated with changes in general economic and business conditions, actions of our competitors, the extent to which we are able to develop new services and markets for our services, the time and expense involved in such development activities, the level of demand and market acceptance of our services, changes in our business strategies and acts of terror against the United States.


Biotech News

Gilead to buy Corus Pharma for $365M and ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement

Biotech News

Gilead to buy Corus Pharma for $365M and ImClone Systems and Merck KGaA Amend and Supplement ERBITUX Agreement


07/21/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Corus Pharma Inc., a privately held biotechnology company, is being sold to Gilead Sciences Inc. for $365 million. Foster City, Calif.-based Gilead (NASDAQ: GILD) secured an exclusive option to purchase the remaining shares of the Seattle company when it invested $25 million in Corus in April. As part of the deal, Gilead said it had paid an undisclosed amount of money to drug giant Novartis A/G to settle a trade secrets lawsuit against Corus. MedImmune, Inc. (Nasdaq: MEDI) announced recently 2006 second-quarter revenues of $73 million and a net loss of $63 million, or $0.26 per share, including share-based compensation expense and as calculated in accordance with generally accepted accounting principles (GAAP). Excluding share-based compensation expense, MedImmune's net loss was $66 million, or $0.27 per share.

ImClone Systems Incorporated (NASDAQ: IMCL) and Merck KGaA, Darmstadt, Germany, announced recently that they have entered into agreements amending and supplementing the 1998 development and license agreement covering ERBITUX® and certain other work in the field of EGFR-targeted antibodies. As part of the agreements, ImClone Systems consented to Merck's sublicense of certain intellectual property rights relating to the development and commercialization of an anti-EGFR antibody to Takeda Pharmaceutical Company. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.

State Legislator Group Honors Sanofi-Aventis' Debbie Hayes as Private Sector Member of the Year

Biotech News

State Legislator Group Honors Sanofi-Aventis' Debbie Hayes as Private Sector Member of the Year

The American Legislative Exchange Council (ALEC) honored Debbie Hayes as Private Sector Member of the Year on July 21 at the organization's 33rd Annual Meeting. Hayes serves as Senior Manager, State Government Affairs for Sanofi-Aventis Pharmaceuticals.

"Debbie Hayes has been a positive force for ALEC for many years. Her enthusiasm and dedication to the principles of free enterprise and limited government is of great note," said 2006 National Chairman, Kansas State Senator Susan Wagle. "She's been a great friend of ALEC, and we're proud to honor her as our Private Sector Member of the Year."

ALEC is the nation's largest nonpartisan, individual membership organization of state legislators, with over 2,400 legislator members from all fifty states and 96 members serving in the U.S. Congress.

"I think ALEC is a wonderful organization. I especially enjoy the Task Forces and the excellent manner in which this combines the perspectives from both the public and private sectors," said Hayes.

Hayes is responsible for state lobbying and regulatory activity for the states of Arkansas, Louisiana, Mississippi, and Oklahoma for Sanofi-Aventis. She began her career in the pharmaceutical industry in 1981 with William H. Rorer, Inc. which has evolved into Sanofi-Aventis through several corporate mergers. She has a B.S. in Pharmacy and Pharm D. from the University of Arkansas College of Pharmacy and a Master's in Public Administration from the University of Arkansas. Debbie currently resides in Little Rock, Arkansas.

Serono Under Attack [Fool.com: Motley Fool Take] July 27, 2006

Serono Under Attack
By Brian Lawler (TMFBreakerBrian)
July 27, 2006

When I was growing up, I was always the last kid picked to play on the dodgeball court. So when biopharmaceutical company Serono (NYSE: SRA) put itself up for sale last year and nobody bought it, I could really empathize.

After you see Serono's second-quarter earnings numbers, which came out on Wednesday, you understand why the company wanted to sell itself last year. The numbers weren't terrible, but competitive pressures loom large for the future.



More

Invitrogen Adds Genetix ClonePixFL Technology To Process Development Services

Invitrogen Adds Genetix ClonePixFL Technology To Process Development Services


Genetix Group plc (LSE: GTX) and Invitrogen Corporation (Nasdaq:IVGN) announced today an agreement which allows Invitrogen to utilize the Genetix ClonePixFL technology in process development services offered through PD-Direct(TM). The Genetix ClonePixFL is an instrument that automatically images, selects and picks mammalian cell colonies based upon a number of parameters such as size, roundness and proximity to neighbors or far more specific information such as quantitative protein secretion or specific protein production.

"The Genetix ClonePix technology greatly enhances our ability to rapidly screen clones for the highest producers," said Dr. Steve Feldman, PD-DirectTM Senior Scientist. "Genetix has developed an excellent tool and we are excited to make this technology available to our process development clients."

"The pairing of Invitrogen's cell line expertise with the high-throughput capability enabled by the Genetix ClonePixFL technology will lead to a step change in the way that cell biology is approached and the efficiency of cell line generation and engineering" said Genetix CSO Julian F. Burke PhD.

Invitrogen also announced that it will develop applications which integrate the ClonePixFL together with the RevolutionTM technology to further enhance the optimization of parental cell lines and production clones.

About Genetix

Genetix provides applications for cell biology, proteomic and genomic research. It supplies many leading academic institutions worldwide and major international pharmaceutical and Biotechnology companies involved in the drug discovery process. These include GSK, AstraZeneca and Novartis.

About Invitrogen

Through PD-Direct(TM), Invitrogen enables clients to access novel technologies such as Genetix ClonePix, Simcell, and Revolution to solve critical issues for bioproduction. The integration of impactful technologies uniquely positions Invitrogen to customize parental cell lines, rapidly screen for high producing clones, and quickly identify optimal bioreactor conditions. PD-Direct(TM) brings over a decade of experience in process development and manufacturing for viral, cell culture, microbial, and cell therapy products. Invitrogen provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 professionals and had revenues of approximately $1.2 billion in 2005. For more information, visit http://www.invitrogen.com.

Through its R&D expertise and scientific resource, Genetix is committed to the continual development of innovative solutions to accelerate the rate of global scientific discovery. The Company made a significant contribution to the Human Genome Project by supplying high-throughput instruments to seven of the eight leading laboratories of the consortium. Currently Genetix' cell biology instrumentation is finding wide acceptance in the Biopharmaceutical industry.

The company employs 100 people globally and had revenues of approximately $20m in 2005.

Genetix is quoted on the London Stock Exchange (LSE: GTX) and is based in New Milton, Hampshire, UK, with offices in the USA and Germany. More information about the Genetix ClonePix technologies can be found at.

Genetix Group Plc
http://www.genetix.com


Biotech News

Amgen Update on Presentation Materials for Webcast and Novavax Receives Positive Results from Pre-Clinical Studies of Influenza Vaccines

Amgen Update on Presentation Materials for Webcast and Novavax Receives Positive Results from Pre-Clinical Studies of Influenza Vaccines


City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/20/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Amgen (Nasdaq:AMGN), the world's largest biotechnology company, announced that as part of its efforts to continuously improve its investor communications, it intends to provide a slide presentation with its upcoming second quarter financial results conference call, scheduled for Thursday, July 20, 2006 at 2 p.m. Pacific Daylight Time. The slide presentation will be posted in the Investor section of the company's Web site (www.amgen.com/investors) in advance of the company's conference call. Nabi Biopharmaceuticals (Nasdaq: NABI) will announce second quarter 2006 financial results on Wednesday, July 26, 2006, after market close. The company will host a conference call and live webcast at 4:30 p.m. ET. The live webcast can be accessed at the Nabi Biopharmaceuticals website at http://www.nabi.com.

Novavax Inc. (Nasdaq: NVAX) said recently that it has received positive results from several pre-clinical studies relating to the company's pandemic and seasonal influenza vaccines, which are under development. Scientists at the University of Pittsburgh and the Southern Research Institute in Birmingham, Ala., have been collaborating with Novavax to test the company's virus-like particle (VLP) vaccines for various strains of influenza. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.



Biotech News

Genentech Acquires Rights to Cancer Treatment and Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease

Genentech Acquires Rights to Cancer Treatment and Genzyme Begins Phase 2 Trial of Oral Treatment for Gaucher Disease


City of Industry, CA --(www.FinancialNewsUSA.com)-- 07/27/2006 - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Genentech (NYSE: DNA) has entered into an agreement with a small biotech firm to develop treatments for cancer and acute heart problems. The company struck a deal with privately held Inotek Pharmaceuticals for the rights to its Phase II poly-ADP polymerase (PARP) inhibitor program, which is designed to block an enzyme that is thought to help tumor cells repair themselves following chemotherapy, thereby increasing its effectiveness. Biogen Idec Inc. (Nasdaq: BIIB) reported a big boost in revenue during its fiscal 2006 second quarter, but the biotechnology company generated a sizable net loss because of one-time expenses stemming from corporate acquisitions. Cambridge, Mass.-based Biogen said revenue reached $660 million during the quarter ending June 30, up from $606 million in the fiscal 2005 second quarter.

Genzyme Corporation (Nasdaq: GENZ) recently announced that it has begun to treat patients in a Phase 2 clinical trial of Genz-112638, an oral therapy being developed for the treatment of Gaucher disease. Genzyme will conduct the study in patients with Type 1 Gaucher disease at medical centers in Europe, Israel, South America and the United States. Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Dutton Associates updates its coverage of NutraCea (OTCBB:NTRZ) maintaining its rating at Strong Buy with a target price of $1.80. The 10-page report by Dutton senior analyst Gerald F. LaKarnafeaux, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals. On October 4, 2005, the merger of NutraCea and RiceX was completed. The benefits of the merger to NutraCea are substantial.



Biotech News

Wednesday, July 26, 2006

IntraOp Medical Receives Order for First Mobetron(R) in China; IntraOp Secures 19th Mobetron Order Worldwide

IntraOp Medical Receives Order for First Mobetron(R) in China; IntraOp Secures 19th Mobetron Order Worldwide

July 26, 2006--IntraOp Medical Corporation (OTCBB: IOPM) has received an order for its first Mobetron System in China. It will be the fourth Mobetron acquired by a hospital in Asia, and the 19th worldwide.


The Mobetron is an FDA-approved, easily transportable electron-beam instrument designed for intraoperative electron radiation therapy (IOERT), or the direct application of radiation to a tumor while a patient is undergoing cancer surgery. This first Chinese order will be installed at Beijing Tumor Hospital, China's premier cancer research and treatment center, often called the "National Cancer Institute of China," and a part of Beijing University Medical Center. In addition to treating patients, the hospital will use the Mobetron to train other Chinese practitioners in the use of IOERT and develop and expand the use of IOERT throughout China.

"Working with Beijing Tumor Hospital is a noteworthy opportunity for IntraOp Medical, the Mobetron and IOERT in general. Not only does this institution influence other cancer programs in China, it also has outstanding clinical research facilities," said Dr. Donald Goer, President and Chief Executive Officer of IntraOp. "We are expecting the Tumor Hospital to take an active role in coordinating IOERT studies throughout the Far East."

Dr. Peter Yu, IntraOp's Director of Far East Operations, said: "We have been working diligently to place a Mobetron at this prestigious center. Many other cancer hospitals in China will be watching to see how well the Mobetron integrates with Beijing Tumor Hospital's cancer program, and we expect other hospitals to follow its lead. From my discussions with the Tumor Hospital staff, I have learned that, in addition to the treatment of advanced and recurrent disease, which is typical of centers with IOERT capability, this hospital will use the Mobetron to treat lung cancer and early-stage breast cancer as well."

About Beijing Tumor Hospital

Beijing Tumor Hospital is the teaching, research and treatment hospital of the Beijing University Medical School, focusing on the prevention, treatment and rehabilitation of cancer patients. With 400 beds, the institution treats 6,000 patients per year. In addition to a modern radiotherapy department, the center boasts one of the most advanced tumor molecular biology laboratories in the world.

About IntraOp Medical Corporation

IntraOp Medical Corporation improves the quality of life for cancer patients through the development, manufacturing and sales of its proprietary Mobetron system. The Mobetron is a mobile electron-beam accelerator designed exclusively for intraoperative electron radiation therapy (IOERT), the direct application of radiation to a tumor while a patient is undergoing cancer surgery. The system makes IOERT widely available, cost effective, and simple to deliver because it is easily transportable between operating rooms and does not require a cost-prohibitive, radiation shielded surgical suite. The system is FDA-certified for sale in the United States and has received the equivalent foreign approvals: CE Mark in Europe, JIS in Japan and SDA in China. IntraOp Medical Corporation is based in Sunnyvale, California. For more information please visit www.intraopmedical.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Luminex Corporation Receives Research Grant from the Department of the Army

Luminex Corporation Receives Research Grant from the Department of the Army
Tuesday July 25, 1:02 pm ET
Research Will Employ the Company's Chip-Scale xMAP Technology

Luminex Corporation (Nasdaq: LMNX - News), a leading multiplex solution developer, today announced that the Company has received a research grant from the Defense Advanced Research Projects Agency (DARPA), which will be administered through the Department of the Army's U.S. Army Research Office. The $300,000 research grant covers a 12- month period and will focus on developing the Company's emerging chip-scale xMAP® technology for bio-defense applications. The chip-scale concept is a radically new approach that leverages Luminex's proven flagship xMAP technology, which is a bead-based flow cytometry solution for multiplexing biological assays, to perform the detection of bio-pathogens on the scale of a micro-chip.



Dr. John Carrano, vice president of research and development of Luminex Corporation, stated, "A successful and practical solution for bio-sensors to combat terrorism will require a compact, and relatively inexpensive detector capable of doing species identification with high sensitivity and specificity; that is precisely the goal of the chip-scale xMAP technology project."

Commenting on the announcement, Patrick Balthrop, president and chief executive officer of Luminex Corporation, added, "We are very pleased to have been awarded this initial grant by DARPA, which will enable us to leverage our state-of-the-art technology and increase our market awareness within the government sector. This opportunity will also make Luminex more competitive for future research grants that utilize our systems and technology."

About Luminex

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry. The Company's xMAP® system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained on the Internet at http://www.luminexcorp.com.

Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle, Luminex's ability to scale manufacturing operations, potential shortages of components, competition, the timing of regulatory approvals and any modification of the Company's operating plan in response to its ongoing evaluation of its business, as well as the risks discussed under the heading "Risk Factors" in Luminex's Annual Report on Form 10-K for the year ended December 31, 2005, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Applied Biosystems Innovation Enables Accurate, Quantitative Gene Expression Analysis

Applied Biosystems Innovation Enables Accurate, Quantitative Gene Expression Analysis of Very Small or Rare Samples; TaqMan(R) PreAmp Master Mix Kit Addresses Unmet Need to Generate Robust Real-Time PCR Results From Limited Amounts of RNA


Jul 26, 2006 - Applied Biosystems (NYSE:ABI), an Applera Corporation business, today announced the launch of a commercial reagent mix that enables accurate, quantitative, real-time gene expression analysis on very small or rare samples. The TaqMan(R) PreAmp Master Mix Kit is intended to address the challenge faced by researchers working with precious samples to extract enough mRNA to perform advanced gene expression analyses using real-time PCR (polymerase chain reaction).

Real-time PCR is a laboratory method used to simultaneously quantify and amplify DNA. Previous commercially available pre-amplification methods designed to analyze small samples using real-time PCR have been limited in their effectiveness because they inconsistently amplify the starting material, resulting in biased and inaccurate gene amplification. These methods are also typically laborious and time-intensive for researchers, with some methods requiring more than ten hours of manual steps and PCR cycling time. As a result, many of these samples remain archived as opposed to being studied for the important molecular information they may contain.



The TaqMan PreAmp Master Mix Kit addresses this challenge with an optimized formulation that works with a multiplexed pool of up to 100 TaqMan Gene Expression Assays. The result is a 1,000-16,000-fold increase in gene transcripts available for analysis. The simple process enables researchers to perform uniform and unbiased amplification of as little as one nanogram of cDNA, and takes only 15 additional minutes of hands-on time and 1.5 hours of PCR cycling time. Researchers can then conduct up to 200 real-time PCR reactions per pre-amplification reaction without compromising their available sample material.

Researchers at the Fox Chase Cancer Center are using the TaqMan PreAmp Master Mix Kit to analyze its laser microdissected samples of hepatitis C-infected liver cells.

"Using the TaqMan PreAmp Master Mix Kit we achieved nearly 100% efficient amplification of our target sequences with reproducible results using varying numbers of cells as starting material," said Renata Coudry, M.D., Ph.D., manager for Fox Chase Cancer Center's laser capture microdissection facility. "The balance of targets in the sample remains the same, enabling truly quantitative analysis. This new amplification method will expand the use of gene expression profiling to characterize limited cell populations, including virus-infected cells."

The TaqMan PreAmp Master Mix Kit accepts from one to 250 nanograms of cDNA generated using random primers. The kit is optimized for use with the TaqMan Gene Expression Assay product line and the Applied Biosystems family of Real-Time PCR Systems.

"We developed the TaqMan PreAmp Master Mix Kit in response to requests from clinical researchers working with laser capture microdissected samples, needle biopsies, paraffin-embedded tissues and other samples with limited amounts of RNA," said Carl Hull, vice president and general manager for sequence detection systems at Applied Biosystems. "As a result, our customers now have access to a robust way to stretch limited samples, perform real-time, quantitative analysis on more gene targets and even conduct gene expression analysis on samples that were previously impossible to study."

More information is available at http://preamp.appliedbiosystems.com.

About Applera Corporation and Applied Biosystems

Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. The Celera Genomics Group is primarily a molecular diagnostics business that is using proprietary genomics and proteomics discovery platforms to identify and validate novel diagnostic markers, and is developing diagnostic products based on these markers as well as other known markers. Celera Genomics maintains a strategic alliance with Abbott Laboratories for the development and commercialization of molecular, or nucleic acid-based, diagnostic products, and it is also developing new diagnostic products outside of this alliance. Through its genomics and proteomics research efforts, Celera Genomics is also discovering and validating therapeutic targets, and it is seeking strategic partnerships to develop therapeutic products based on these discovered targets. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.

Applied Biosystems Forward Looking Statements

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should, "planned," and "expect," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For Research Use Only. Not for use in diagnostic procedures.

Purchase of TaqMan(R) PreAmp Master Mix includes an immunity from suit under patents specified in the product insert to use only the amount purchased for the purchaser's own internal research. No other patent rights are conveyed expressly, by implication, or by estoppel. Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA.

Copyright(C) 2006. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera and Celera Genomics are trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc.

Contact Applied Biosystems Nicole Litchfield, 415-793-6468 (Media) nicole.litchfield@appliedbiosystems.com Peter Fromen, 650-638-5828 (Investor Relations) fromenpj@appliedbiosystems.com

Bio-Imaging Technologies

Bio-Imaging Technologies to Release Second Quarter 2006 Financial Results and Host Conference Call on August 2, 2006
July 26, 2006--Bio-Imaging Technologies, Inc. (NASDAQ: BITI) will release its financial results for the second quarter ended June 30, 2006 on Wednesday, August 2, 2006.


Management of Bio-Imaging Technologies, Inc. will host a conference call on the same day at 11 a.m. EDT to discuss the company's financial results and achievements. Those who wish to participate in the conference call may telephone (888) 335-6674 from the U.S. or (973) 935-2981 for international callers, passcode 7673206 approximately 15 minutes before the call. There will be a simultaneous webcast on www.bioimaging.com. A digital replay will be available by telephone for two weeks and may be accessed by dialing (877) 519-4471, from the U.S., or (973) 341-3080, for international callers, passcode 7673206. The replay will also be on the website under "Investor Relations" at www.bioimaging.com for two weeks.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA and its European Core Lab in Leiden, The Netherlands. Through its CapMed division, Bio-Imaging provides the Personal HealthKey(TM) technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of the proposed acquisition, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance.

STEM CELL WORK GETS STATES' AID AFTER BUSH VETO

STEM CELL WORK GETS STATES' AID AFTER BUSH VETO
Written by JODI RUDOREN
Tuesday, 25 July 2006
President Bush’s veto of legislation to expand federally financed embryonic stem cell research has had the unintended consequence of drawing state money into the contentious field and has highlighted the issue in election campaigns across the country.


Two governors seized the political moment Thursday, the day after the veto, to raise their ante for stem cell research.


Gov. Arnold Schwarzenegger of California, a Republican who helped Mr. Bush win a second term but has long disagreed with him on this research, cited the veto as he lent $150 million from the state’s general fund to pay for grants to stem cell scientists. In Illinois, Gov. Rod R. Blagojevich, a Democrat opposed to most every White House initiative, offered $5 million for similar grants in his state.


Before the announcements, the only money available was $72 million that five states had allocated for the research and $90 million that the National Institutes of Health had provided since 2001 for work on a restricted number of stem cell lines.


More

Monday, July 24, 2006

Biotech News - The biotechnology culture clash

The biotechnology culture clash

Embedded religious perspectives in East and West create distinct
responses to genetic engineering

By Lee M. Silver
(July 18, 2006)


EAST AND WEST: Different views of humanity's place in the natural
world give rise to varying perspectives on the appropriate use of
biotechnology.
(Source: AngMoKio/Wikimedia Commons)
In the year 2000, my family and I spent nine months traveling across
Asia. Since then I have traveled across most other areas of the
world, most recently sub-Saharan Africa, talking to people about
their spiritual beliefs and what they think about biotechnology in
particular. I will describe my interpretations of what I saw and
heard.

Differences in religious perspectives

If you look at the national law/political climate of embryonic
research, you will notice three different areas: America, Europe
(Mendocino, Calif., I include with Europe) and Asia. Asia, including
Singapore, has a very liberal political climate when it comes to
embryo research in contrast to the other two regions. Conversely,
you get a very different picture in Europe and America on
genetically engineered crops. In America you have positive national
laws and political climate for genetically modified (GM) crops,
whereas Europeans reject GM crops. And in Asia they accept GM. So
you have these three different categorical responses to these two
different technologies. Europe and America are essentially inverse,
but Asia accepts everything.

http://www.stnews.org/News-2909.htm

------------------------ Yahoo! Groups Sponsor --------------------~-->
See what's inside the new Yahoo! Groups email.
http://us.click.yahoo.com/3EuRwD/bOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Biotechnology puts corn in latest fashion offerings

Biotechnology puts corn in latest fashion offerings
Homegrown crop being used as fiber in clothing

By Paul Elias
Associated Press

In a sneak peek of what could be fashion's future, leggy models
draped in dresses by designers like Oscar de la Renta and Versace
strut their stuff on the runway.

But it is no Paris or New York fashion show. Rather, the scene is a
Toronto biotechnology conference, and the dresses are made from a
new fiber called Ingeo, made largely from genetically engineered
corn.

The Biotechnology Industry Organization used the fashion statement
last week to burnish its battered image as an environmental scourge.

Biotechnology is quietly playing a growing role in an apparel
industry waking up to its customers' concerns about the environment
and the reliance on foreign oil used to make synthetic fabrics like
polyester and nylon. But the trend is raising concerns among some
environmental purists who oppose genetically engineered crops of any
kind.

http://www.lsj.com/apps/pbcs.dll/article?
AID=/20060718/NEWS03/607180320/1004/news03

------------------------ Yahoo! Groups Sponsor --------------------~-->
See what's inside the new Yahoo! Groups email.
http://us.click.yahoo.com/3EuRwD/bOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Kreatech Biotechnology BV Launches the First Complete kit for Whole Genome Ampli

Kreatech Biotechnology BV Launches the First Complete kit for Whole
Genome Amplification and Labeling for arrayCGH Analysis
Monday July 24, 5:33 am ET

Kreatech Biotechnology BV (www.kreatech.com) announces the launch of
the "Genome-pULSe, arrayCGH Whole Genome Amplification and Labeling
Kit" the latest addition to their product portfolio for arrayCGH
analysis.


This kit combines QIAGEN's whole genome amplification (WGA)
technology, which allows amplification of very small amounts of
genomic DNA isolated from tissue or cells, with KREATECH's ULS(TM)
reagents necessary to label these samples for arrayCGH analysis,
thereby offering a more complete solution to scientists carrying out
arrayCGH analysis. The Genome-pULSe Kit is available with the ULS
(TM) labeling molecule bound to Cy(TM)3 and Cy(TM)5 dyes licensed
from GE Healthcare. The WGA technology included in the kit is the
REPLI-g® kit from QIAGEN.

ArrayCGH analysis of particular samples, such as small needle tumor
biopsies, can be limited by the small amount of sample available.
Traditional methods of genomic DNA amplification include the time-
consuming process of creating EBV-transformed cell lines followed by
whole genome amplification using random or degenerate
oligonucleotide-primed PCR. However, all PCR-based methods can
generate non-specific amplification artefacts, resulting in the
incomplete coverage of loci. In addition to this, conventional
methods that are based on enzymatic incorporation of modified
nucleotides used to label the amplified DNA for subsequent
microarray analysis could further increase the bias in locus
representation.

The Genome-pULSe Kit delivers a novel procedure for the uniform
amplification and subsequent direct (non-enzymatic) labeling of
whole genome DNA from small samples. This method has been designed
to provide a quick and highly reproducible amplification and
labeling procedure for arrayCGH analysis.

"The combination of the ULS technology with REPLI-g in the Genome-
pULSe Kit enables us to deliver a unique product to researchers."
said Brent Keller, General Manager, Kreatech USA and VP Commercial
Operations, Kreatech Biotechnology BV. "It combines the advantage of
QIAGEN's Phi29 driven Whole Genome DNA Amplification with the
direct, non-enzymatic ULS labeling technology. With the unique
combination of ULS and REPLI-g, customers looking for amplification
of small input volumes of genomic DNA for microarray applications
will now be able to amplify and label directly for arrayCGH
analysis. This is the first amplification and labeling kit available
for arrayCGH analysis that enables customers to detect genetic
aberrations without introducing bias during the amplification and
labeling unlike conventional amplification and enzymatic labeling
procedures".

The Genome-pULSe kit further completes KREATECH's arrayCGH product
line. In June 2005 the company released the "ULS(TM) arrayCGH
Labeling Kits". The ULS arrayCGH labeling kit has the unique feature
of allowing the user to label genomic DNA directly in a one step
labeling reaction (30 minutes), avoiding the need for a potentially
biasing enzymatic step. This results in more accurate data as well
as saving time. The ULS labeling efficiency is independent of
fragment length making it ideal for use with archival DNA.

KREATECH's ULS technology relies on the special binding properties
of platinum to form coordinative bonds with biomolecules by binding
to specific sites on DNA, RNA and proteins. In this way, ULS acts as
relatively simple "molecular glue" for DNA, RNA and proteins. As a
result of its versatility, customers can attach any kind of
molecular label to ULS and then bind the labeled ULS complex to the
biomolecules of interest. Since the ULS technology does not require
the enzymatic incorporation of modified nucleotides into RNA or DNA,
it does not introduce bias.

QIAGEN's REPLI-g® technology is based on Multiple Displacement
Amplification, which carries out isothermal genome amplification
utilizing a uniquely processive DNA polymerase capable of
replicating 100 kb without dissociating from the genomic DNA
template. The DNA polymerase has a proofreading activity to maintain
high fidelity during replication and provide highly uniform "bias
free" DNA amplification across the entire genome.

About KREATECH

KREATECH Biotechnology B.V., a private company founded in 1990,
focuses on the creation, development, production and marketing of
innovative diagnostic and life science products. KREATECH's
proprietary Universal Linkage System (ULS(TM)) offers a reliable,
robust and easy to use non-enzymatic technology that can be applied
to a broad range of biomolecules and labeling agents. KREATECH is
committed to achieve and maintain the highest standards in
production and Quality Control as well as in the relationships with
our customers and partners. The company's quality policies are
demonstrated by the implementation of ISO 9001 (2000) and ISO 13485
(GMP 2003) guidelines. More information on KREATECH can be accessed
at www.kreatech.com.

---------------------------------------------------------------------
-----------
Source: Kreatech Biotechnology B.V.

------------------------ Yahoo! Groups Sponsor --------------------~-->
See what's inside the new Yahoo! Groups email.
http://us.click.yahoo.com/3EuRwD/bOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Biotechnology industry is important to region

Biotechnology industry is important to region
Experts stress good jobs, growth as evidence of vital businesses in
expanding scientific field

By ERIC ANDERSON, Deputy business editor

Taconic Farms just reached $100 million in sales. Employment at
AngioDynamics Inc. is at 300 people. And Albany Molecular Research
Inc. added research facilities in such places as Singapore and India
as it competes globally.
These were among the data offered Wednesday to illustrate the
growth, and the growing importance, of the biotechnology industry on
the Capital Region's economy, as a group of industry officials
visited the Times Union.


The industry faces challenges, including declining federal support
for basic research.

National Institutes of Health funding is down 10 percent to 15
percent from last year, said Eugene Schuler, chairman of Bioconnex,
a regional biotechnology networking and support organization
affiliated with the Albany-based Center for Economic Growth.

http://timesunion.com/AspStories/story.asp?
storyID=501180&category=BUSINESS&BCCode=HOME&newsdate=7/20/2006

------------------------ Yahoo! Groups Sponsor --------------------~-->
Something is new at Yahoo! Groups. Check out the enhanced email design.
http://us.click.yahoo.com/TktRrD/gOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - $2.3M additional funding supports Marine Biotechnology Research Centre


$2.3M additional funding supports Marine Biotechnology Research Centre

Rimouski, QC - The federal government has committed to an additional
$2.3 million in funding for the Marine Biotechnology Research Centre
(MBRC). The money will support the centre's R&D and technology
transfer activities for the next three years.

The Marine Biotechnology Research Centre is the only marine centre of
its kind in Canada. It is part of a maritime science and technology
cluster in the Bas-Saint-Laurent. Through its research, technology
transfer, business services and technological watch activities, it has
become a hub for the development of marine biotechnologies and their
transfer to Quebec and other Canadian firms.

http://www.labcanada.com/issues/ISArticle.asp?id=57831&issue=07042006

------------------------ Yahoo! Groups Sponsor --------------------~-->
Great things are happening at Yahoo! Groups. See the new email design.
http://us.click.yahoo.com/SktRrD/hOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Genedata and Insilico Biotechnology in Systems Biology Collaboration

Genedata and Insilico Biotechnology in Systems Biology Collaboration

STUTTGART, Germany & BASEL, Switzerland July 18 2006 - Genedata and
Insilico Biotechnology will work together using systems biology to
support life science companies enhance their biotechnological
production methods. The collaboration will combine Genedata's
computational systems for genomics data management and analysis with
Insilico's pathway simulation tools.

Systems biology probes the workings of biological pathways using a
combination of simulation techniques and genome-wide, high
throughput data. The approach finds application in fields such as
metabolic engineering and nutrigenomics, and is increasingly used
for disease modeling and in drug discovery.

The collaboration between Genedata and Insilico will focus on
biotechnological challenges in the fine chemical, food, feed and
personal care sectors. Target applications include guiding the
development of high-performance microbial production strains used in
industrial fermentation. The collaboration will support life science
research, for example, at Degussa and the Kluyver Centre for
Genomics and Industrial Fermentation.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Tuesday, July 18, 2006

Biotech News - Biotech Boom

Biotech Boom
Bay Area is the Epicenter of this Leading-Edge Technology
Published: July 16, 2006
By Julia Hollister

The biotech field may have the cure for your career search – a
promising job in a profession that's expanding faster than you can
spell biotherapeutics.

There are over 1400 biotech companies in the United States and the
Bay Area is home to the lion's share. The state recognized the
region's preeminence in biotech when officials named San Francisco
home to the California Institute of Regenerative Medicine (stem cell
research), which will eventually pump $3 billion into biotech
grants. But the industry isn't waiting for those public funds to
expand dramatically.

<a href="http://www.jobjournal.com/article_full_text.asp?
artid=1756">Biotech Boom&#65533;(California Job Journal)</a>

------------------------ Yahoo! Groups Sponsor --------------------~-->
Great things are happening at Yahoo! Groups. See the new email design.
http://us.click.yahoo.com/TISQkA/hOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Maryland biotech seeks about $50 million in IPO

Maryland biotech seeks about $50 million in IPO
Washington Business Journal - 2:28 PM EDT Tuesdayby Neil AdlerStaff Reporter
Print this Article Email this Article Reprints RSS Feeds Most Viewed Most Emailed
The public market for local biotechnology companies continues to stink.

The latest evidence is Osiris Therapeutics, which filed in May to go public, hoping to raise $80 million. This week, the Maryland stem-cell research company amended its IPO application with the Securities and Exchange Commission, and the new information indicates it expects to raise between $44 million and $52 million.


In the new filing, Osiris says it intends to offer 3.5 million shares of common stock at $11 to $13 a share.

more

Sunday, July 16, 2006

Biotech News - Arizona Legislature OKs $35 million for biotech

Arizona Legislature OKs $35 million for biotech

The Business Journal of Phoenix - June 21, 2006

The Arizona Legislature has given the green light to a controversial
biotechnology incentive fund aimed at attracting more research and
science-related jobs to the state.

The Arizona House of Representatives gave the final sign-off on the
bill late Tuesday by a 41-to-15 vote.


Supporters included moderate Republicans and Democrats, while a
number of conservatives voted against the measure questioning how
the money will be used and whether the state should be giving
incentives to businesses and investing in the risky biotech sector.

The approved plan puts $35 million toward the Arizona 21st Century
Competitive Initiative Fund, aimed at helping to attract
biotechnology to the state.

http://washington.bizjournals.com/phoenix/stories/2006/06/19/daily28.
html

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

------------------------ Yahoo! Groups Sponsor --------------------~-->
Check out the new improvements in Yahoo! Groups email.
http://us.click.yahoo.com/6pRQfA/fOaOAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News - Arizona biotech firms make mark on Fortune list

Biotech News - Arizona biotech firms make mark on Fortune list


 The Business Journal of Phoenix - June 27, 2006

by Cathy Luebke

The business Journal

 

Biotech companies Ventana Medical Systems Inc. and Matrixx Initiatives Inc. were the only Arizona representatives on the annual Fortune Small Business 100 list of the nation's fastest growing small public companies. Ventana (NASDAQ:VMSI) was No. 35 on the 2006 list, down slightly from its 28th place ranking last year. The Tucson company reported revenue of $199 million and net income of $25.5 million for 2005. Both figures represent growth of about 20 percent over 2004. Ventana facilitates the analysis of tissue samples in the treatment of cancer and other diseases.

 

http://www.bizjournals.com/phoenix/stories/2006/06/26/daily11.html

 

Biotech

__._,_.___

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/





SPONSORED LINKS
Biology Biotech research Biotech companies
Biology book Biotechnology company Biotechnology jobs


YAHOO! GROUPS LINKS




__,_._,___

DNA Laboratory Sponsors Locator Technology


DNA Laboratory Sponsors Locator Technology

Chromosomal Laboratories, Inc., a leading DNA testing laboratory announced a sponsorship of the MySpace Guardian Toolbar from the rapidly growing MySpace website. The financial support helps protect parents and children from potential predators that may be lurking on the increasingly popular website.

Phoenix, AZ, USA, July 14, 2006 -- The use of the MySpace Guardian Toolbar allows users to search a database of registered sex offenders in various geographical regions as well as by name, alias and other features. Information about these predators is displayed along with photographs. The service even allows users to notify proper authorities if they think they have been contacted by one of these sexual predators.

Chromosomal Laboratories has been at the forefront of protecting children with their Child Identification Kits and DNA profiling services. The company also utilizes advanced DNA technologies for family reconstruction, paternity cases, and provides forensic DNA analyses for law enforcement. Sponsoring an internet service that also protects children was a natural fit for the company. Chromosomal Laboratories will also provide a free download link for the important safety feature at their website which can be found at www.chromosomal-labs.com.

“If we can help prevent one child or one adult from being the victim of a sexual predator by sponsoring this service then we have accomplished a great thing,” stated Vladimir Bolin, CEO of Chromosomal Laboratories. “We encourage all parents to download this toolbar to help protect their families and most importantly their children.”

Individuals interested in this important internet safety feature should visit www.chromosomal-labs.com or www.myspaceguardian.net. The download is completely free to users and is an important security tool for all parents.

About Chromosomal Laboratories, Inc.:
Chromosomal Laboratories, Inc. is a full service analytical testing company that specializes in providing advanced DNA analyses for a variety of industries, which include paternity, forensic, lineage, genealogy, animal pedigree, genetically modified organisms, and ancestry cases. Chromosomal Laboratories also provides research and development in DNA diagnostics as well as DNA consulting services. The company is based in Phoenix, Arizona.

Chromosomal Laboratories, Inc. is strategically headquartered in Phoenix, Arizona, an area rich in biotech industries and home to the Translational Genomics Research Institute and the International Genomics Consortium. Chromosomal Laboratories’ state of the art 10,000 square foot facility is equipped with advanced instrumentation for genetic analyses.


Arizona Biotech
Arizona Biotech News

Arizona Legislature OKs $35 million for biotech

Arizona Legislature OKs $35 million for biotech

The Business Journal of Phoenix - June 21, 2006

The Arizona Legislature has given the green light to a controversial biotechnology incentive fund aimed at attracting more research and science-related jobs to the state.

The Arizona House of Representatives gave the final sign-off on the bill late Tuesday by a 41-to-15 vote.


Supporters included moderate Republicans and Democrats, while a number of conservatives voted against the measure questioning how the money will be used and whether the state should be giving incentives to businesses and investing in the risky biotech sector.

The approved plan puts $35 million toward the Arizona 21st Century Competitive Initiative Fund, aimed at helping to attract biotechnology to the state.

MORE

Biotech
Biotech News

We're No. 5! We're No. 5!

We're No. 5! We're No. 5!
Actually, Phoenix fans, hold those cheers

JonTalton

And before some recent efforts, Phoenix was AWOL on the biotechnology revolution that is improving health and the economy elsewhere. In 2002, the Brookings Institution named Seattle the fifth-largest biotech center. Phoenix, it said, had no significant research or commercialization. No wonder San Diego comes in fifth in National Institutes of Health funding.

More

Biotech
Biotech News

Monday, July 10, 2006

Biotech News - Mesa schools focus on biotechnology training

Mesa schools focus on biotechnology training

Josh Kelley
The Arizona Republic
Jul. 7, 2006 12:00 AM

http://www.azcentral.com/arizonarepublic/mesa/articles/0707mr-
labconstruction0707Z11.html

Mesa Public Schools is spending nearly $4.5 million to construct and
renovate biology labs and classrooms at five high schools where
educators are expanding biotech programs.

Changes include filling empty rooms with lab equipment and building
a structure with classrooms and lab space.

The school district's investment in training more students in
biotechnology comes as the demand for lab technicians and
researchers rises with Arizona's growing bioscience industry.
advertisement

Beginning this fall, some Mesa students in biotech classes will have
the chance to begin working on a research project that involves
decoding the genome of a bacteria and publishing the results.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/